Lazertinib is a third generation EGFR inhibitor approved in some countries, such as the Republic of Korea, for the treatment of locally advanced or metastatic NSCLC in patients with T790M mutation [196]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.